UPLIZNA - Display Banners Conference - 40257

Test Your ECTRIMS on NMOSD Knowledge!

Dec 14, 2022

A quiz based on the latest NMOSD news and research from ECTRIMS.

ECTRIMS NMOSD eBook

Dec 7, 2022

ECTRIMS NMOSD 2022a.indd

Ravulizumab Significantly Reduces Relapses in AQP4+ NMOSD

Nov 8, 2022

Treatment with ravulizumab was highly effective in reducing risk for relapse in patients with...

Inebilizumab Effective in NMOSD Despite Fc Receptor Polymorphisms

Nov 8, 2022

For a presentation at the 2022 European Committee for Treatment and Research in Multiple Sclerosis...

Patients With NMOSD Cognitively Impaired Regardless of Serostatus

Nov 4, 2022

A prospective, longitudinal, multicenter study of 217 patients with neuromyelitis optica spectrum...

New Data on the Safety of Anti-CD20 mAbs Around Pregnancy

Nov 4, 2022

A new study suggests B-cell depleting anti-CD20 monoclonal antibodies (mAbs) such as ocrelizumab...

NMOSD: True AQP4 Seroconversion Is Rare

Nov 4, 2022

At a prize-winning poster presented at the European Committee for Treatment and Research in...

The ECTRIMS 2022 – 38th Congress of the European Committee for Treatment and Research of Multiple Sclerosis, has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 18 European...

ECTRIMS 2022: Why Attend?

Oct 21, 2022

Planning committees developed an interesting and diverse scientific program. Well-known session formats such as Scientific Sessions, Hot Topics or Meet the Experts are being brought back again this year The schedule also offers...